Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.84 |
| ▸ | FAAH | O00519 | 2/20 | 0.73 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.73 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | ADH1B | P00325 | 1/20 | 0.48 |
| ▸ | ADH1C | P00326 | 1/20 | 0.48 |
| ▸ | ADH1A | P07327 | 1/20 | 0.48 |
| ▸ | ADH4 | P08319 | 1/20 | 0.48 |
| ▸ | ADH7 | P40394 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | EP300 | Q09472 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10448536 | 1.00 | TSHR (0.84) | TSHRFAAHTRPV1EPHX1ADH1B | |
| SCHEMBL27740716 | 1.00 | TSHR (0.84) | TSHRFAAHTRPV1EPHX1ADH1B | |
| SCHEMBL27719663 | 1.00 | TSHR (0.84) | TSHRFAAHTRPV1EPHX1ADH1B | |
| SCHEMBL350393 | 1.00 | TSHR (0.84) | TSHRFAAHTRPV1EPHX1ADH1B | |
| SCHEMBL7189299 | 1.00 | TSHR (0.84) | TSHRFAAHTRPV1EPHX1ADH1B | |
| SCHEMBL349758 | 0.97 | TSHR (0.80) | TSHRFAAHTRPV1EPHX1ADH1B | |
| SCHEMBL7180877 | 0.95 | TSHR (0.75) | TSHRFAAHTRPV1EPHX1ADH1B | |
| SCHEMBL351608 | 0.92 | TSHR (0.71) | TSHRFAAHTRPV1EPHX1ADH1B | |
| SCHEMBL9815185 | 0.92 | TSHR (0.71) | TSHRFAAHTRPV1EPHX1ADH1B | |
| SCHEMBL28117030 | 0.92 | TSHR (0.71) | TSHRFAAHTRPV1EPHX1ADH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190201383-A1 | Apparatus and Methods for Preventing or Treating Failure of Hemodialysis Vascular Access and Other Vascular Grafts | VASCULAR THERAPIES INC (US) | 2019-07-04 | — | — | US | disclosed |
| US-10272073-B2 | Apparatus and methods for preventing or treating failure of hemodialysis vascular access and other vascular grafts | VASCULAR THERAPIES, INC. (US) | 2019-04-30 | — | — | US | disclosed |
| EP-2314293-B1 | Implantable device containing resorbable matrix material and rapamycin for preventing or treating vasuloproliferative diseases | VASCULAR THERAPIES LLC (US) | 2017-01-04 | — | — | EP | disclosed |
| US-20150335793-A1 | Medical Implants and Methods for Regulating the Tissue Response to Vascular Closure Devices | VASCULAR THERAPIES INC (US) | 2015-11-26 | — | — | US | disclosed |
| US-9132099-B2 | Medical implants and methods for regulating the tissue response to vascular closure devices | VASCULAR THERAPIES, INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20150209334-A1 | APPARATUS AND METHODS FOR PREVENTING OR TREATING FAILURE OF HEMODIALYSIS VASCULAR ACCESS AND OTHER VASCULAR GRAFTS | VASCULAR THERAPIES, INC. | 2015-07-30 | — | — | US | disclosed |
| US-8858982-B2 | Apparatus and methods for preventing or treating failure of hemodialysis vascular access and other vascular grafts | VASCULAR THERAPIES, LLC (US) | 2014-10-14 | — | — | US | disclosed |
| US-20140065198-A1 | Medical Implants and Methods for Regulating the Tissue Response to Vascular Closure Devices | VASCULAR THERAPIES LLC (US) | 2014-03-06 | — | — | US | disclosed |
| EP-1638624-B1 | VASCULAR CLOSURE DEVICE | VASCULAR THERAPIES LLC (US) | 2013-10-30 | — | — | EP | disclosed |
| EP-2314293-A1 | Implantable device containing resorbable matrix material and rapamycin for preventing or treating vasuloproliferative diseases | Vascular Therapies, LLC (US) | 2011-04-27 | — | — | EP | disclosed |
| EP-1351681-B1 | IMPLANTABLE DEVICE CONTAINING RESORBABLE MATRIX MATERIAL AND ANTI-PROLIFERATIVE DRUGS FOR PREVENTING OR TREATING FAILURE OF HEMODIALYSIS VASCULAR ACCESS AND OTHER VASCULAR GRAFTS | VASCULAR THERAPIES LLC (US) | 2010-09-15 | — | — | EP | disclosed |
| US-20080091263-A1 | Apparatus and Methods for Preventing or Treating Failure of Hemodialysis Vascular Access and Other Vascular Grafts | VASCULAR THERAPIES, INC. | 2008-04-17 | — | — | US | disclosed |
| EP-1638624-A2 | MEDICAL DEVICES AND METHODS FOR REGULATING THE TISSUE RESPONSE TO VASCULAR CLOSURE DEVICES | Vascular Therapies, LLC (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20050004158-A1 | Medical implants and methods for regulating the tissue response to vascular closure devices | VASCULAR THERAPIES LLC (US) | 2005-01-06 | — | — | US | disclosed |
| WO-2004112864-A2 | MEDICAL DEVICES AND METHODS FOR REGULATING THE TISSUE RESPONSE TO VASCULAR CLOSURE DEVICES | VASCULAR THERAPIES LLC (US) | 2004-12-29 | — | — | WO | disclosed |
| US-20040197409-A1 | a prosthetic device (sleeve) placed on the outside surface of the vessel or graft which then elutes antiproliferative drugs or agents from a drug-eluting matrix material; flexible, cylindrical, bioabsorbing, agent-eluting matrix with a vascular-sized lumen | VASCULAR THERAPIES, LLC | 2004-10-07 | — | — | US | disclosed |
| US-6726923-B2 | PROSTHETIC DEVICE PLACED ON THE OUTSIDE SURFACE OF THE VESSEL OR GRAFT WHICH THEN ELUTES ANTIPROLIFERATIVES FROM A MATRIX | VASCULAR THERAPIES, LLC | 2004-04-27 | — | — | US | disclosed |
| EP-1351681-A2 | IMPLANTABLE DEVICE CONTAINING RESORBABLE MATRIX MATERIAL AND ANTI-PROLIFERATIVE DRUGS FOR PREVENTING OR TREATING FAILURE OF HEMODIALYSIS VASCULAR ACCESS AND OTHER VASCULAR GRAFTS | Vascular Therapies, LLC (US) | 2003-10-15 | — | — | EP | disclosed |
| US-20030113359-A1 | Prosthetic device placed on the outside surface of the vessel or graft which then elutes antiproliferatives from a matrix | VASCULAR THERAPIES, LLC | 2003-06-19 | — | — | US | disclosed |
| WO-2002062335-A2 | IMPLANTABLE DEVICE CONTAINING RESORBABLE MATRIX MATERIAL AND ANTI-PROLIFERATIVE DRUGS FOR PREVENTING OR TREATING FAILURE OF HEMODIALYSIS VASCULAR ACCESS AND OTHER VASCULAR GRAFTS | VASCULAR THERAPIES, LLC (US) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150335793-A1 | Medical Implants and Methods for Regulating the Tissue Response to Vascular Closure Devices | TGFB1, RICTOR, MMP1 | TSHR 3556/4885FAAH 2234/4885TRPV1 2540/4885 |
| US-20140065198-A1 | Medical Implants and Methods for Regulating the Tissue Response to Vascular Closure Devices | TGFB1, RICTOR, MMP1 | TSHR 3556/4885FAAH 2234/4885TRPV1 2540/4885 |
| US-20050004158-A1 | Medical implants and methods for regulating the tissue response to vascular closure devices | TGFB1, RICTOR, MMP1 | TSHR 3556/4885FAAH 2234/4885TRPV1 2540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.